Incyte, Merck shares slide after melanoma therapy fails study

Incyte shares fell 20 percent in premarket trading, while Merck shares were down about 2 percent.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>